NIH-funded research R01 grant

Faster diagnosis and better brain health after HIV-associated meningitis

Official title: Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis

Funded at University of Minnesota · NIH-11141078 · Data updated 2026-11-12

This project tests faster bedside and lab tests plus a new oral antifungal to help adults with HIV who develop meningitis.

More AIDS research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Minnesota
NIH-funded
Lab location1 site (Minneapolis, United States)
Project startSeptember 1, 2013
Project endMay 31, 2029
Funding year2025
Award (this year)$297,733
NIH project number5R01NS086312-12
Project IDNIH-11141078 on NIH RePORTER

Who could benefit from this research

Could help

Adults living with HIV who present to participating hospitals with suspected or confirmed central nervous system infection or meningitis would be the ideal candidates.

Less likely to help

People without HIV, children, patients with non-infectious neurological problems, or those who cannot attend participating sites are unlikely to benefit from joining this project.

What this research studies

If I join, researchers will enroll over 1,000 adults with HIV and suspected meningitis, mainly in Uganda. My spinal fluid and blood may be checked with rapid point-of-care and molecular tests, including a semi-quantitative cryptococcal antigen lateral flow and a new host-response TB test (Xpert-HR), to find the cause quickly. The team will also run a randomized phase II trial giving some participants an oral antifungal called oteseconazole to see if it clears the fungus better. The study will follow my recovery and memory/brain function over time to track neurocognitive outcomes.

Why it matters

Potential benefit: If successful, this work could speed up correct diagnoses and offer a safer, easier oral treatment that improves survival and brain function after HIV-related meningitis.

How similar studies have gone: Rapid cryptococcal antigen tests and molecular TB diagnostics have improved diagnosis in other studies, but the semi-quantitative CrAg-SQ, Xpert-HR host-response signature, and oteseconazole for cryptococcosis in humans are relatively new and not yet proven.

Where this research is happening

  • University of Minnesota
    Minneapolis, United States
    Active

Researchers

  • Principal investigator: Boulware, David R — University of Minnesota
  • Study coordinator: Boulware, David R

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.